5-hydroxytryptamine receptor 2A — Drug Target
All drugs that target 5-hydroxytryptamine receptor 2A — marketed and clinical-stage. Includes 13 drug classes acting on this target.
Drug classes
Atypical Antipsychotic [EPC] · Atypical Antipsychotic · Ergot Derivative · Nucleoside Analog Antifungal [EPC] · loxapine · 5-HT2 receptor antagonist, Peripheral vasodilator · Tricyclic Antidepressant [EPC] · methysergide · High Risk QT Prolonging Agents · chlorprothixene · ketanserin · Sulfonamide Antibacterial [EPC]
Marketed (15)
- Caplyta · Intra-Cellular · Atypical Antipsychotic [EPC] · Neuroscience
Caplyta works by binding to the 5-hydroxytryptamine receptor 2A, which helps to regulate dopamine and serotonin levels in the brain. - Nuplazid · Acadia Pharms Inc · Atypical Antipsychotic · Neuroscience
Nuplazid works by blocking the action of a specific chemical messenger in the brain called serotonin. - Latuda · Sunovion Pharms Inc · Atypical Antipsychotic · Neuroscience
Latuda works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2A, which helps to regulate mood and reduce symptoms of psychosis. - Carphenazin · Neuroscience
- Methergine · Edison Theraps Llc · Ergot Derivative · Hematology
- Ancobon · Bausch Health · Nucleoside Analog Antifungal [EPC] · Metabolic
- Adasuve · loxapine · Neuroscience
- Praxilene · Merck Serono (originally Lipha) · 5-HT2 receptor antagonist, Peripheral vasodilator · Metabolic
A 5-HT2 receptor antagonist that improves peripheral blood flow and cellular metabolism by blocking serotonin-mediated vasoconstriction and enhancing aerobic metabolism in ischaemic tissues. - Amoxan · Pfizer · Tricyclic Antidepressant [EPC] · Neuroscience
- Deseril · methysergide · Neuroscience
- Alimix · High Risk QT Prolonging Agents · Cardiovascular
- Taractan · Roche · chlorprothixene · Neuroscience
- Ketensin · ketanserin · Cardiovascular
- Sulfadiazine · Eli Lilly · Sulfonamide Antibacterial [EPC] · Immunology
- Fanapt · Vanda Pharms Inc · Atypical Antipsychotic [EPC] · Metabolic
Fanapt works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2A, which helps to reduce symptoms of schizophrenia.